StemBioSys
San Antonio, US · Delaware corporation · 1 known investors
StemBioSys develops cell culture technology, including the patented CELLvo Matrix that replicates the body's physiological microenvironment to expand mesenchymal stem cells and specialty cells while preserving their stem-like properties. It supplies cells and cell expansion tools for stem cell research and regenerative medicine applications.
Founders & leadership
JC
Jean CheeverDirector
CX
Chen Xiao-DongDirector
MD
Mark D HorseyExecutive Officer
RH
Robert HutchensDirector
JW
John W FeikDirector
SD
Steven DavisCo-founder
CB
Catherine BurzikDirector
RS
Robert S LangerDirector
TB
Travis BlockChief Technology Officer
XC
Xiao-Dong ChenCo-founder
IC
Ian ClementsDirector
PC
Paul CastellaDirector
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$1.5MofferedDec 2020 · BiotechnologyRule 506(b)
▶$1.5MofferedDec 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ian ClementsDirector
- Steven DavisDirector
- Mark HorseyExecutive Officer
- Becky CapDirector
- Xiao-Dong ChenDirector
- Robert HutchensExecutive Officer, Director
- Robert LangerDirector
- John W FeikDirector
- Catherine BurzikDirector
- Jean CheeverDirector
- Paul CastellaDirector
- Offering amount
- $1.5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KofferedJan 2020 · BiotechnologyRule 506(b)
▶$500KofferedJan 2020 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Xiao-Dong ChenDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Mark HorseyExecutive Officer
- Paul CastellaDirector
- Robert LangerDirector
- John FeikDirector
- Ian ClementsDirector
- Jean CheeverDirector
- Robert HutchensExecutive Officer, Director
- Offering amount
- $500K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedJun 2019 · 32 investors · BiotechnologyRule 506(b)
▶$1.4MraisedJun 2019 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ian ClementsDirector
- John W FeikDirector
- Robert HutchensExecutive Officer, Director
- Robert S LangerDirector
- Paul CastellaDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Mark HorseyExecutive Officer
- Jean CheeverDirector
- Xiao-Dong ChenDirector
- Offering amount
- $3M
- Amount sold
- $1.4M
- First sale
- May 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.1MraisedMay 2018 · 47 investors · BiotechnologyRule 506(b)
▶$4.1MraisedMay 2018 · 47 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jean CheeverDirector
- Ian ClementsDirector
- Chen Xiao-DongDirector
- Mark D HorseyExecutive Officer
- Robert HutchensDirector
- John W FeikDirector
- Paul CastellaDirector
- Steven DavisDirector
- Catherine BurzikDirector
- Robert S LangerDirector
- Offering amount
- $4.3M
- Amount sold
- $4.1M
- First sale
- Apr 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2023 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $143K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.